Cosmetic preparation for topical application comprising novel peptides for improving skin appearance and regeneration

Adjusting the skin signal transmission path through specific peptides or peptide derivative compositions solves the skin regeneration and maintenance problems in the prior art, and achieves significant improvement in the appearance and long-term stability of the skin, enhances the skin regeneration ability, and reduces the risk of side effects.

CN114929192BActive Publication Date: 2024-12-03ASC REGENITY LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202180009978.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-21
Filing Date
2021-01-18
Publication Date
2024-12-03
Estimated Expiration
2041-01-18

AI Technical Summary

Technical Problem

The prior art is difficult to effectively promote and maintain healthy skin, especially in the case of aging or damaged skin. Traditional intervention methods have limited efficacy and potential side effects, making it difficult to improve skin status stably in the long run.

Method used

Using specific novel peptide or peptide derivative compositions, including Wnt/β-catenin signaling pathway agonists, EPOR/CD131 receptor agonists, and TGF-β3 variants, to form Trigger factor complexes to promote skin regeneration and maintenance.

Benefits of technology

It has achieved significant improvement in the appearance and long-term stability of the skin in the short term, enhanced skin regeneration ability, reduced wrinkles and signs of aging, avoided dryness and dullness of the skin, and reduced the risk of adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114929192B_ABST
    Figure CN114929192B_ABST
Patent Text Reader

Abstract

The present invention relates to novel naturally derived and synthetic active peptides or peptide-derived agents designed for cosmetic treatment of human skin, and cosmetic preparations and compositions containing them. The active agents can effectively restore, promote and maintain healthy skin. In particular, the present invention discloses a combination or group of said skin-effective agents including stem cell factors, which regulate the skin microenvironment and regulate the behavior of skin stem cells, thereby effectively healing, regenerating and improving the condition of aged or damaged skin.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to novel naturally derived and synthetic active peptides or peptide-derived agents designed for cosmetic treatment of human skin, and cosmetic preparations and compositions containing them. The active agents are effective in restoring, promoting and maintaining healthy skin.

[0002] In particular, the present invention discloses a combination or group of said skin effective agents including stem cell factors, which triggers the repair and regeneration of skin cells, thereby effectively healing and improving the condition of aged or damaged skin through synergistic effects or through joint alleviation of undesirable effects. According to the present invention, these new groups of agents and factors are referred to as "trigger factor complexes". Background of the Invention

[0004] Skin homeostasis and wound healing

[0005] Human skin is one of the main barriers of the human body to the outside world and is constantly exposed to destructive damage. In order to prevent the continuous decline of skin condition, biology has developed various regenerative mechanisms. In the steady state, the continuous renewal of cells in the skin epithelium requires the shedding of old cells on the surface and the compensatory generation of new cells to replace the lost cells. After more serious injuries such as trauma (wounds), irradiation, chemical damage or inflammation, the accumulation of damage signals in the skin leads to the development of complex innate repair programs. In both steady-state cell renewal and specialized repair programs, stem cells and progenitor cells act as key executors of skin maintenance. In both cases, they will eventually provide new cells to replace old and lost cells. Generally, the specialized repair program follows four stages: (I) hemostasis (in the case of open wounds), (II) inflammation, (III) proliferation, and (IV) tissue remodeling. Both processes (including their sub-stages) of steady-state cell renewal and specialized repair programs must be strictly regulated. For example, the misregulation of cell proliferation caused by failure to limit the generation of new cells in both steady state and specialized repair programs can lead to cancer initiation. On the contrary, failure to provide enough new cells slows down the regeneration process and impairs the barrier function of the skin. Similarly, failure to limit or stop inflammation can lead to chronic inflammatory diseases, local tissue degeneration, stem cell pool exhaustion or autoimmune diseases. On the contrary, failure to produce an appropriate and profound inflammatory response to destructive damage leads to an inability to fully exert regenerative capacity, which also impairs the barrier function of the skin and faces the risk of opportunistic infection. At the level of tissue remodeling, failure to initiate this stage will cause the skin to have a temporary organization with impaired function, such as lack of skin attachments and suboptimal extracellular matrix composition. On the contrary, failure to terminate the tissue remodeling stage will also lead to incorrect extracellular matrix composition and may promote fibrosis. Therefore, the body has formed complex mechanisms to coordinate the orderly execution of skin maintenance and repair programs. However, additional complexity is due to the fact that tissue regeneration does not always have a linear path with a series of predetermined steps. When the innate repair mechanism is overwhelmed, for example due to very large trauma, aging or persistent damage and the associated exhaustion of regenerative capacity, functional repair is impaired, and the "damage control" program that ultimately leads to scar formation is initiated.

[0006] Stem Cells

[0007] Stem cells and progenitor cells contribute to skin healing by providing new cells. Depending on the skin compartment, different stem cell populations give rise to functional skin cells. The epidermis is the outermost layer of the skin, and cell renewal in both steady state and re-epithelialization after injury is primarily mediated by epidermis-resident stem cells. Most of the epidermal surface is covered by the interfollicular epithelium (IFE); other epithelial structures of the skin epithelium include hair follicles and sweat glands. Different stem and progenitor cell populations reside in their own niches within the skin epithelium: Stem cells in the IFE (Itg2α 高、Itg1α 高 ), progenitor cells in IFE (Inv + ,Lgr6 + ), stem cells in the infundibulum (Lrig1 + ), stem cells in the sebaceous gland ducts (Gata6 + ), stem cells in the isthmus and sebaceous glands (Lrig1 + ,Lgr6 + ,Blimp1 + ,Plet1 + ), and stem cells in the bulge region (K15 + 、K19 + 、Lgr5 + 、CD34 + 、Sox9 + 、Tcf3 + )( Dekoninck and Blanpain, 2019, Nature Cell Biology, 21(1), 18-24. ). All of these cells may contribute to the temporary IFE epithelium replenishment in wounds. In addition, skin-resident mesenchymal stem cells (MSCs) ( Crigler et al., 2007, The FASEB Journal, 21(9), 2050 - 2063 ) and hematopoietic stem cells (HSC) (Fan et al., 2006,Experimental Hematology, 34(5), 672-679) However, of all these sources, IFE stem and progenitor cells are the largest contributors to epithelial cell function in both short-term and long-term repair after trauma. (Blanpain and Fuchs, 2014, Science, 344(6189) MSCs have been reported to reside in defined niches in the dermal papilla (DP) and connective tissue sheath (CTS) of hair follicles. (Lau, Paus, Tiede, Day and Bayat, 2009, Experimental Dermatology, 18(11), 921-933) Furthermore, the dermal and epidermal compartments are not isolated from each other but communicate and cooperate with each other. For example, MSCs participate in paracrine loops together with keratinocytes and their precursors to stimulate re-epithelialization (Lau et al., 2009).

[0008] Mesenchymal stem cells (MSCs) are key players in skin homeostasis, cell renewal, ECM dynamics, and tissue regeneration. MSCs replenish the mesenchymal cell pool, participate in ECM protein deposition and degradation, and regulate tissue dynamics through the secretion of growth factors and cytokines. Various subclasses of MSCs are present in different niches in the skin (Hu, Borrelli, Lorenz, Longaker, & Wan, 2018, Stem Cells International , 2018, 1-13). These include hair follicle (HF) resident cells (such as dermal sheath cells and dermal papilla cells), interfollicular MSCs in the dermis, vasculature-associated pericytes, and adipose-derived MSCs in the subcutaneous tissue. In addition, the contribution of MSCs, primarily bone marrow-derived, infiltrating from the vasculature into the skin has been reported. Stem cells are generally defined by the ability to self-renew and differentiate into functional cell types. The past distinction between MSC / fibroblasts and stem cell status is being debated, as conventional fibroblasts are morphologically indistinguishable from MSCs and formally meet the defining criteria for (multipotent) stem cells. (Soundararajan and Kannan, 2018, Journal of Cellular Physiology. Wiley-Liss Inc, December 1). Regardless of their classification, the role of fibroblasts in skin homeostasis, ECM dynamics, and wound healing is well established (Rognoni and Watt, 2018, Trends in Cell Biology, 28(9), 709-722 ). Nevertheless, mesenchymal phenotypic diversity is further elaborated by dermis-associated lineages such as papillary (upper dermis) and reticular (lower dermis) fibroblasts. (Driskell et al., 2013, Nature, 504(7479), 277 - 281 ). The papillary lineage has a "pro-regenerative" phenotype and is required for hair follicle formation, whereas the reticular lineage is required for rapid wound closure but also contributes to the deposition of fibrosis-associated ECM in a "pro-scarring" manner. Mesenchymal cell heterogeneity has also been studied at the molecular level (Philippeos et al., 2018, Journal of Investigative Dermatology, 138(4), 811-825; Vaculik et al. People, 2012, Journal of Investigative Dermatology, 132(Part 3 1), 563-574) , and more detailed lineage associations have been recently reviewed ( Lynch and Watt, 2018 ).

[0009] Furthermore, in addition to the phenotypic diversity associated with the microenvironment (dermis) in mesenchymal cells, intrinsic cell heterogeneity also exists and is a major determinant of regenerative behavior. One major factor is the Engrailed-1 (En-1) status. (Jiang et al., 2018, Nature Cell Biology, 20(4), 422 - 431 ; Rinkevich et al., 2015, Science, 348(6232) ). En-1-negative fibroblasts (ENFs) mediate scarless wound healing during embryonic development. However, ENF numbers decline after embryonic development, and En-1-positive fibroblasts (EPFs) become the dominant lineage and promote scar formation.

[0010] Characteristics of aging skin

[0011] In aged skin, cellular replacement declines, barrier function and mechanical protection are impaired, wound healing and immune responses are delayed, thermoregulation is impaired, and sweat and sebum production are reduced. (Farage, Miller and Maibach, 2010, Textbook of Aging Skin, 1-1220).Reduced cell renewal rates can lead to roughness, delayed wound healing and uneven pigmentation. Older people suffer from dry skin more often than young, healthy individuals. This is based on the reduced function of the sebaceous glands to produce natural moisturizing factors and lipids in the stratum corneum, resulting in a reduction in the lamellar bilayer and a poorer water retention capacity. Skin aging is also accompanied by extensive remodeling of the extracellular matrix (ECM) in the dermis, senescence of skin fibroblasts, a significant upregulation of matrix metalloproteinases (MMPs) and a reduction in collagen production. The resulting general shortage and breakage of collagen, elastic fibers and other ECM proteins leads to a loss of tensile strength, manifested as wrinkles and skin sagging. In addition, the flattening of the dermal papilla leads to a greater risk of blister formation and subsequent infection.

[0012] Regeneration of damaged skin and scar formation are associated with signaling molecular patterns

[0013] Biological processes are regulated at various levels, including cellular and molecular. Cells, including stem cells, integrate internal states and external signals for biological decision making. Likewise, physiological skin homeostasis and regeneration are controlled by specific sets of signaling molecules that act at specific times and locations.

[0014] Enhanced skin regeneration through triggering factors

[0015] Although it is able to maintain functional skin in most cases, the body's homeostasis and self-repair mechanisms are not perfect. This can be exacerbated, for example, by the occurrence of very large trauma, exhaustion of repair capacity triggered by chronic activation, aging, epigenetic loss or other acute or chronic diseases or stressors.

[0016] However, shortcomings of the innate regulatory system can be mitigated or even overcome by external regulation. When functional restoration is the goal, external regulation often requires an approach to overcome regulatory deadlock. In turn, this often prescribes a multi-pronged approach targeting multiple regulatory centers. However, conventional interventions often contain a "one entity one target" strategy and are therefore of limited effectiveness. In addition, short-term improvements are often unrelated to overcoming regulatory deadlocks, leading to continued reliance on short-term regulation. For example, anti-inflammatory drugs provide good short-term relief by limiting inflammation without overcoming regulatory deadlocks or allowing functional restoration. Therefore, once the drug is discontinued, inflammation often recurs.

[0017] Previous attempts to harness the regenerative power of stem cells, which have relied on supplying the skin with external stem cells from various sources, have shown limited success.

[0018] EPOR-CD131 agonist peptide-lipid complexes and conjugates initially presented an elegant alternative when used in combination with vasodilators (International Patent Application WO 2018 / 086732, U.S. Patent 10,456,346). These agents have proven to be beneficial in cosmetic formulations in short-term applications, but less beneficial or even harmful during long-term application. SUMMARY OF THE INVENTION

[0020] exist First In one aspect, the present invention relates to single novel peptides or peptide-derived agents that are effective, alone or in combination, in regenerating and maintaining human skin. These agents are characterized by the peptide sequences / formulas presented by SEQ ID NOs: 1-19, which are described in more detail in the following sections.

[0021] exist second In one aspect, the present invention relates to a cosmetic preparation or composition for topical application to the skin, comprising at least one peptide or peptide derivative that triggers or enhances or improves skin regeneration or appearance, wherein the at least one peptide or peptide derivative is selected from the group consisting of peptides and peptide derivatives that stimulate the Wnt / β-catenin signaling pathway (A), and comprises or has the sequence / formula:

[0022] (i) LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL (SEQ ID NO: 1)

[0023] (ii) LNPSECPKTVLGASTSTLDASYSTAEAENHVRL (SEQ ID NO: 2)

[0024] (iii) Z1-LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL (SEQ ID NO: 3)

[0025] (iv) Z1-LNPSECPKTVLGASTSTLDASYSTAEAENHVRL (SEQ ID NO: 4)

[0026] wherein Z1 is a carrier moiety covalently linked to the N-terminus of the peptide which reduces tissue penetration and / or transbasement membrane permeation of the peptide.

[0027] In a preferred embodiment of the present invention, Z1 is polyethylene glycol (PEG) having a molecular weight in the range of 8 - 60 kDa, preferably 20 - 40 kDa.

[0028] exist thirdIn one aspect, the present invention relates to a cosmetic preparation or composition for topical application to the skin, comprising at least one peptide or peptide derivative that triggers or enhances or improves skin regeneration or appearance, wherein at least one peptide or peptide derivative is selected from the group consisting of peptides and peptide derivatives that are agonists of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor (B), and comprises or has the sequence / formula:

[0029] (v) GGGGETTNMWAREWMGLPCQDQ (SEQ ID NO: 5)

[0030] (vi) Z2-GGGGETTNMWAREWMGLPCQDQ (SEQ ID NO: 6)

[0031] wherein Z2 is an acyl group of a branched or unbranched fatty acid covalently linked to the N-terminus of the peptide.

[0032] In a preferred embodiment of the present invention, Z2 is a branched or unbranched fatty acid having 5 to 42 carbon atoms, preferably 5 to 25 carbon atoms, for example Z2 is myristoyl.

[0033] In a further preferred embodiment of the present invention said peptide / peptide derivative based agonist represented by SEQ ID NO 5 or 6 is partially or completely inactivated during application, preferably by air oxidation of methionine residues within the peptide sequence.

[0034] In another preferred embodiment of the present invention, the cosmetic preparation or composition further comprises an appropriate amount of a peptide / peptide derivative-based antagonist of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor, wherein the antagonist modulates or reduces or inhibits the biological activity of the agonist presented by SEQ ID NO 5 or 6.

[0035] In a preferred embodiment of the present invention, the antagonist comprises or has the sequence / formula

[0036] GGGGETTNMWAHDWMGLPRADQ (SEQ ID NO: 17) or

[0037] Z2 - GGGGETTNMWAHDWMGLPRADQ (SEQ ID NO: 10)

[0038] wherein Z2 is an acyl group of a branched or unbranched fatty acid of 5 to 42 carbon atoms attached to the N-terminus of the peptide.

[0039] In a further preferred embodiment of the present invention said peptide / peptide derivative based antagonist represented by SEQ ID NO 10 or 17 is partially or completely inactivated during application, preferably by air oxidation of methionine residues within the peptide sequence.

[0040] The modulation of the activity of the EPOR / CD131 agonists and / or antagonists by oxidation of methionine residues in the sequence of the agent by atmospheric oxygen is another important discovery of the present invention.

[0041] exist fourth In one aspect, the present invention relates to a cosmetic preparation or composition for topical application to the skin, comprising at least one peptide or peptide derivative that triggers or enhances or improves skin regeneration or appearance, wherein at least one peptide or peptide derivative is selected from the group consisting of peptides and peptide derivatives that are human TGF-β3 variants (C) and comprises or has a sequence / formula

[0042] (vii) ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPC

[0043] PYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQ

[0044] LENMVVKSCKCS (SEQ ID NO: 7)

[0045] (viii) ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPC

[0046] PYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQ

[0047] LENMVVKSCKCSLP X TGGG (SEQ ID NO: 8)

[0048] (ix) ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPC

[0049] PYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQ

[0050] LENMVVKSCKCSLP X TGGG-Z3 (SEQ ID NO: 9)

[0051] wherein X is K or E, and Z3 is a sugar polymer attached to the C-terminus.

[0052] In a preferred embodiment of the present invention, Z3 is or comprises an oligomer or a multimer or a polymer comprising 15-50, preferably 18-30 monomer units comprising a trehalose or trehalose derivative moiety.

[0053] It can be shown here that trehalose derivative monomer units such as 4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose or Q-6-deoxy-trehalose (Q-6doTh) are preferably suitable according to the invention. The attachment of Z3 at the C-terminus of the TGF-ß3 peptide sequences of SEQ ID No. 7 and 8 (yielding the peptide derivative of SEQ ID NO: 9) leads to a longer-term stability of the resulting fusion molecule, which is important for cosmetic preparations and corresponding skin applications.

[0054] Therefore, TGF-ß3 fusion peptide,

[0055] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLENMVVKSCKCSLP X TGGG-[4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose] n (SEQ ID NO: 18), and

[0056] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLENMVVKSCKCSLP X TGGG-[Q-6doTh] n (SEQ ID NO: 19), wherein X is K or E, and n is an integer between 15 and 50, represents a particularly preferred embodiment of the present invention.

[0057] The peptide or peptide derivative as specified by any one of SEQ ID NOs: 1-19 may optionally be encapsulated in or attached to a liposome or ceramide structure to improve release properties during application.

[0058] It should be emphasized that each of the above mentioned peptides may be individually effective in the cosmetic skin treatments described above and in more detail below.

[0059] Nevertheless, the inventors of the present invention could show that a combination of two or three peptides, each peptide being selected from a different set (A), (B) and (C) as specified above and below, forming a so-called trigger factor complex for cosmetic skin applications, is much more effective and shows synergistic results in terms of the skin treatment effect and long-term stability of the cosmetic preparations, compared to preparations containing only each single agent.

[0060] Therefore, in The fifth And in an important key aspect, the present invention provides a group or trigger factor complex of the reagents for topical cosmetic application to the skin, which comprises at least one peptide or peptide derivative of any one of the sets (A), (B), (C) mentioned above and below and at least one peptide or peptide derivative of a different set.

[0061] In other words, the present invention provides

[0062] (I) a first trigger factor complex comprising one or more peptides or peptide derivatives of set (A) and one or more peptides or peptide derivatives of set (B);

[0063] (II) a second trigger complex comprising one or more peptides or peptide derivatives of set (A) and one or more peptides or peptide derivatives of set (C);

[0064] (III) a third trigger complex comprising one or more peptides or peptide derivatives of set (B) and one or more peptides or peptide derivatives of set (C); and

[0065] (IV) a fourth trigger complex comprising one or more peptides or peptide derivatives of set (A) and One or more peptides or peptide derivatives of set (B) and One or more peptides or peptide derivatives of set (C).

[0066] Each trigger factor complex exhibits improved skin treatment properties compared to a corresponding cosmetic preparation or composition comprising only a single peptide component from any one of sets (A) or (B) or (C).

[0067] However, according to the invention, the most effective and therefore preferred is the trigger factor complex (IV) which comprises at least one peptide or peptide derivative of set (A) and At least one peptide or peptide derivative of set (B) and At least one peptide or peptide derivative of set (C).

[0068] In more detail, a trigger factor complex is preferred, which comprises

[0069] (i) one or more peptides or peptide derivatives selected from the group consisting of:

[0070] LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL (SEQ ID NO: 1),

[0071] LNPSECPKTVLGASTSTLDASYSTAEAENHVRL (SEQ ID NO: 2),

[0072] Z1-LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL (SEQ ID NO: 3),

[0073] Z1-LNPSECPKTVLGASTSTLDASYSTAEAENHVRL (SEQ ID NO: 4), and

[0074] (ii) one or more peptides or peptide derivatives selected from the group (A) consisting of:

[0075] GGGGETTNMWAREWMGLPCQDQ (SEQ ID NO: 5)

[0076] Z2-GGGGETTNMWAREWMGLPCQDQ (SEQ ID NO: 6), and

[0077] (iii) one or more peptides or peptide derivatives selected from the group (A) consisting of:

[0078] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLENMVVKSCKCS (SEQ ID NO: 7),

[0079] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLENMVVKSCKCSLP X TGGG

[0080] (SEQ ID NO: 8),

[0081] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLENMVVKSCKCSLP X TGGG-Z3 (SEQ ID NO: 9),

[0082] wherein Z1, Z2, Z3 and X have the meanings as defined above.

[0083] Furthermore, the mentioned trigger factor complexes as well as compositions comprising only a single peptide or peptide derivative of any one of sets (A), (B) or (C) may contain other agents and / or ingredients effective in cosmetic and skin treatment applications.

[0084] Thus, the inventors have demonstrated that, in addition to the optional presence of the antagonists with SEQ ID NOs 10 and 17 as disclosed above, the corresponding cosmetic preparations according to the invention may further comprise:

[0085] (a) A peptide or a peptide derivative which induces type 3 collagen-derived matrikine activity and comprises or has one of the following sequences / formulas:

[0086] LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG (SEQ ID NO: 11),

[0087] VKGESGKPGANGLSGERGPPGPQG (SEQ ID NO: 12),

[0088] Z2-LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG

[0089] (SEQ ID NO: 13),

[0090] Z2-VKGESGKPGANGLSGERGPPGPQG (SEQ ID NO: 14),

[0091] and / or

[0092] (b) a peptide or peptide derivative which causes CD26 / Dpp4 inhibition and comprises or has one of the following sequences / formulas:

[0093] EIHQEEPIGGQSGSGG-KPI, (SEQ ID NO: 15) EIHQEEPIGGK[Z2]SGSG GK PI (SEQ ID NO: 16),

[0094] wherein Z2 is an acyl group of an unbranched or branched fatty acid having 5 to 42 carbon atoms, such as myristoyl, G - K represents an isopeptide bond between the carboxyl group of G (glycine) and the epsilon amino group of K (lysine), and K[Z2] represents an amide bond between the epsilon amino function of K and the carboxyl function of a fatty acid Z2 (such as myristoyl), with advantageous and improved properties.

[0095] In summary, and taking into account the assumed general mode of action which should be expressly regarded as not binding on the findings of the present invention, the following can be stated:

[0096] This invention provides not only specific single peptide agents, but also novel trigger factor complexes, groups of novel peptides and / or chemical entities that enable the body to harness its innate regenerative capacity to greater potential by overcoming multiple regulatory deadlocks.

[0097] A first key feature of the trigger factor complex according to the present invention is its suitability for use in a variety of injuries and skin conditions requiring a broad spectrum of applications.

[0098] The second key feature of the trigger factor complex according to the present invention is that all of its components can be applied together in one formulation, rather than sequentially in time and space, because the healing process will dictate that it is used for single agent regulation. This is indeed the case, because the regulatory regulation applied by the trigger factor complex cooperates with the local microenvironment. Therefore, the activity of a given subset of the trigger factor complex is only effective when it is timely. For example, the effectiveness of a given subset of the trigger factor complex is required at a given intermediate stage of the healing process. When this is indeed the case, this subset of molecules of the trigger factor complex is always active, i.e. before its effectiveness is required, and even after its effectiveness is required. However, the trigger factor complex utilizes four mechanisms that control the conversion of activity to effectiveness. First, this includes the collaboration and regulation of extracellular and intracellular signal transduction with local time-specific skin state signals, including growth factors, cytokines, chemokines, damage-related molecular patterns, molecules released by neurons, ECM molecules and matrikine. Secondly, this includes the sensitivity of cells to the applied trigger factor complex, i.e., receptivity, such as expressed by cell surface receptors. Third, this includes the use of situational cell responses to the same stimulus that depend on the cell state. This particularly concerns epigenetic states associated with the differentiation state of stem and progenitor cells, both of which in turn are spatially and temporally linked to the microenvironment. Fourth, the local microenvironment of protease activity, pH, and oxidative potential regulates the local availability and activity of active ingredients.

[0099] The third key characteristic of the trigger factor complex is non-interference in the absence of insult. This means that a subset of the trigger factor complex that fights skin condition "A" will not cause adverse effects when applied to skin affected by condition "B" or healthy skin.

[0100] In addition, the trigger factor complex according to the present invention utilizes innate signaling pathways to drive cell behavior. The molecules of the trigger factor complex of the present invention guide stem cell behavior toward a regenerative cell program. This is achieved by modulating the innate cell signaling pathways that normally determine cell behavior.

[0101] Finally, the present invention relates to the use of said cosmetic preparations and isolated peptides or peptide derivatives for topical cosmetic treatments of human skin, including skin repair, skin rejuvenation, natural skin radiance, wrinkle reduction, skin anti-aging and avoidance and improvement of dry, dull and cracked skin. DETAILED DESCRIPTION OF THE INVENTION

[0103] According to the present invention, the term " Peptides " refers to any peptide having a sequence of amino acids covalently linked together by amide bonds, and the term "peptide" expressly includes peptides otherwise named polypeptides.

[0104] According to the present invention, the term " Peptide derivatives " refers to any chemical molecule comprising a peptide portion comprising at least five amino acids covalently linked together by amide bonds, wherein the peptide is covalently linked to a non-peptide portion. Such non-peptide portions expressly include organic chemical residues such as, but not limited to, aliphatic, aromatic, homocyclic, heterocyclic, oligomeric or polymeric portions. In particular, the non-peptide portion includes fatty acids, oligomers / polymers containing trehalose or trehalose derivatives, and conventional pharmaceutical carriers (such as polyethylene glycol).

[0105] As used herein, the term “ Wnt / β-catenin signaling pathway ” refers to the Wnt pathway that causes β-catenin to accumulate in the cytoplasm and eventually translocate into the nucleus to act as a transcriptional co-activator of transcription factors belonging to the TCF / LEF family.

[0106] As used herein, the term " EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor " refers to tissue protective EPO receptor, which contains one or more EPO receptor subunits (EPOR) and one or more cluster of differentiation 131 proteins (CD131). Cluster of differentiation 131 proteins are also known as cytokine receptor common subunit β (CSF2RB) or interleukin-3 receptor common β subunit (IL3RB).

[0107] As used herein, the term “ matrikine " refers to peptides that are derived from fragments of extracellular matrix (ECM) proteins and regulate cell activity by interacting with specific receptors. In the context of the present invention, the matrikine includes peptides that stimulate and regulate tissue regeneration and synthesis of extracellular matrix materials in skin tissue.

[0108] As used herein, the term "trigger factor complex" means a group of peptides, peptide derivatives and / or other chemical entities that enable human skin to utilize its innate regenerative capacity to a greater extent by modulating the skin microenvironment and regulating stem cell behavior.

[0109] Amino acid code :To disclose peptide sequences, conventional single-letter amino acid codes are used herein. For clarity, A represents alanine, C represents cysteine, D represents aspartic acid, E represents glutamic acid, F represents phenylalanine, G represents glycine, H represents histidine, I represents isoleucine, K represents lysine, L represents leucine, M represents methionine, N represents asparagine, P represents proline, Q represents glutamine, R represents arginine, S represents serine, T represents threonine, V represents valine, W represents tryptophan, and Y represents tyrosine.

[0110] TGFβ3 module

[0111] TGFβ signaling is a major regulator of skin homeostasis and regeneration (Gilbert, Vickaryous, & Viloria-Petit, 2016). All TGFβ isoforms (TGFβ1, TGFβ2, TGFβ3) play key roles in wound healing. In simple terms, however, the different isoforms act as natural counterparts. TGFβ1 and 2 promote scar formation by promoting the migration and activation of inflammatory cells, the formation of granulation tissue, and the transition of fibroblasts to myofibroblasts. In contrast, TGFβ3 attenuates the inflammatory process, injury-associated ECM remodeling, and limits the myofibroblast phenotype. Furthermore, the application of TGFβ3 is not limited to macroscopic injuries of the skin, but can also direct cell behavior towards promoting regeneration of skin that has been microinjured or environmentally stressed. Nonetheless, the role of TGFβ in vivo is complex, and the administration of recombinant TGFβ3 does not provide a lasting therapeutic benefit, as demonstrated by the failure of the Phase III clinical study of the TGFβ3 drug Juvista. (Günter and MacHens, 2012, European Surgical Research, 49(1), 16-23) .

[0112] However, the present invention discloses an engineered human TGFß variant, namely TGFß3 T57K L68H S102E, as a suitable agent for supporting healthy skin for cosmetic applications. The construct can be recombinantly produced, for example, from stably expressing CHO cells and has the following amino acid sequence:

[0113] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADT K HSTVLGLYNT H NPEASASPCCVPQDLEPLTILYYVGRTPKVEQL E NMVVKSCKCS (SEQ ID NO: 7).

[0114] Protein stability is a common problem for protein-based products. Many degradation pathways including chemical reactions, unfolding and aggregation lead to loss of activity and the production of potentially harmful byproducts such as immunogenic species, such as oligomers and higher order assemblies. The intended use of proteins in biochemically complex mixtures such as cosmetics poses an even greater challenge to ensure stability. Chemicals commonly used in cosmetics, including lipids, thermodynamically prefer the unfolded protein state with exposed hydrophobic surfaces. Furthermore, cosmetics are rich in seeds for protein aggregation. Indeed, recombinant TGFß3 T57K L68H S012E from mammalian expression hosts was not stable within commercially compatible times in standard cosmetic formulations. Recombinant proteins are often stabilized by excipients. (Kamerzell, Esfandiary, Joshi, Middaugh, and Volkin, 2011, Advanced Drug Delivery Reviews, 63(13), 1118-1159).However, many of these excipients interfere with cosmetic formulations at effective protein stabilization concentrations or interact negatively with other cosmetic ingredients. Another elegant approach to protein stabilization is post-purification glycopolymer-conjugation, which is independent of or in addition to expression-dependent protein glycosylation. (Mancini, Lee and Maynard, 2012, Journal of the American Chemical Society, 134(20), 8474-8479) .

[0115] However, thiol-reactive conjugation is non-specific for cysteine ​​sites, leading to labeling polymorphism and, in addition, to a high risk of labeling-induced non-functional TGFβ species and batch-to-batch variability. This non-specific labeling can be circumvented by utilizing enzyme-catalyzed conjugation based on protein tags. (Falck and Müller, 2018, Antibodies, 7 (1), 4.) For example, a sortase A-based strategy may be employed. In this strategy, the peptide motif LPXTG (eg, where X is K or E) is fused to TGFβ3 or any TGFβ3 variant at the c-terminus and has the following sequence:

[0116] [TGFß3 variant] -LPXTGGG, or specifically TGFß3 T57K L68H S102E:

[0117] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADT K HSTVLGLYNT H NPEASASPCCVPQDLEPLTILYYVGRTPKVEQL E NMVVKSCKCSLPXTGGG

[0118] (SEQ ID NO: 8)

[0119] Such fusion proteins can be produced recombinantly and purified. Protein stability can be enhanced by glycopolymers, such as polyvinyl made from 4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose monomers, preferably 18 or more monomers make up the polymer. In one synthetic strategy, one glycopolymer terminus is chemically coupled to the GGG peptide, for example by chemically functionalizing the polymer terminus with an amino group and forming an amide bond with the carboxyl terminus of the C-terminal glycine. This fusion construct GGG-glycopolymer can be enzymatically conjugated in a site-specific (LPXTG-specific) manner by sortase A via covalent bonding to the LPXTG motif of recombinant TGFβ3 or TGFβ3 variants.

[0120] This resulted in the following fusion molecule:

[0121] [TGFβ3 variant] -LPXTGGG-glycopolymer, or specifically TGFβ3 T57K L68H S102E:

[0122] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADT K HSTVLGLYNT H NPEASASPCCVPQDLEPLTILYYVGRTPKVEQL E NMVVKSCKCSLPXTGGG-Z3

[0123] (SEQ ID NO: 9)

[0124] wherein X is K or E, and Z3 is a sugar polymer linked to the C-terminus, such as a trehalose oligomer.

[0125] In the specific case of a polyvinyl sugar polymer made from n monomers of 4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose, for TGFβ3 T57K L68H S102E, the sequence is as follows:

[0126] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLENMVVKSCKCSLPXTGGG-[4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose] n (SEQ ID NO: 18)

[0127] Furthermore, it is also possible to generate glycopolymers as (poly)peptides by solid phase peptide synthesis from amino acid monomers conjugated to trehalose moieties. (De Bona et al., 2009, Journal of Peptide Science, 15(3), 220- 228.). Solid phase peptide synthesis (SPPS) can be controlled in a stepwise manner by amino acid extension. This provides far more control over the length of the final product than chemical polymerization, as illustrated by the polymerization of 4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose. Therefore, product heterogeneity in SPPS-based strategies is much less than in chemical polymerization-based strategies. In order to implement such SPPS-based strategies, trehalose-conjugated amino acids that are compatible with SPPS (e.g., fmoc / Boc protected) must be used. Those skilled in the art will recognize that there are many ways to produce such reagents. One possibility is to covalently bond amino-functionalized trehalose to the side chain carboxyl functional group of an fmoc-protected amino acid via chemical amidation. More specifically, 6-amino 6-deoxytrehalose (Dutta et al., 2019, ACS Central Science, acscentsci . 8b00962) can be used to specifically amidate the γ-carboxyl function of an α-carboxyl protected α-amino protected glutamic acid. The resulting 6-deoxytrehalose functionalized amide (glutamine derivative), (Q-6doTh) moiety can be used as a building block for SPPS. This may require removal of its α-carboxyl protecting group but retaining its α-amino protecting group, which can be achieved by chemical means. As a result, GGG-(Q-6doTh) can be produced n A polypeptide in which three N-terminal glycine residues are covalently bound to n units of 6-deoxy-trehalose functionalized glutamine. SPPS is able to well control the number n of these 6-deoxy-trehalose functionalized glutamines. In order to stabilize TGFβ3 derivatives, a number n of 18 or greater is desired. This trehalose functionalized peptide can be covalently linked to a TGFβ3 variant-LPXTG fusion by sortase A. Such a TGFβ3 variant-LPXTG fusion protein can be recombinantly produced and purified.

[0128] The above sortase-mediated conjugation produces the following fusion molecule: [TGFβ3 variant]-LPXTGGG-[Q-6doTh] n , or specifically TGFβ3 T57K L68H S102E:

[0129] ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADT K HSTVLGLYNT H NPEASASPCCVPQDLEPLTILYYVGRTPKVEQL E NMVVKSCKCSLPXTGGG-[Q-6doTh] n (SEQ ID NO:19), wherein n is an integer between 15 and 50.

[0130] The TGFβ3 variant conjugated to the above structure preferably comprising 18 or more trehalose variant moieties is stable, e.g., resistant to unfolding and resistant to aggregation, for at least 6 months at 30°C in standard cosmetic preparations including emulsions. In this context, resistance to unfolding is defined as retention of >95% of the folded state as measured by circular dichroism (CD) spectroscopy. Aggregation resistance is defined as low (<1%) relative abundance of oligomeric species of >4 times the molecular weight of the monomer or more as measured by dynamic light scattering (DLS). In order to perform CD spectroscopy and DLS measurements on the purified protein, the TGFβ3 variant is extracted from the cosmetic preparation by dialysis in a large flow chamber. The dialysis membrane pores are large enough to allow the TGFβ3 variant to permeate across the membrane. The TGFβ3 variant protein is simultaneously concentrated from the dilute solution by affinity chromatography.

[0131] The preferred concentration range of such stable TGFβ3 variant conjugates in the final cosmetic product is 80 pM to 500 nM.

[0132] Stem Cell Homeostasis Module

[0133] Stem cells are key mediators of tissue development, homeostasis, renewal, and regeneration following injury. In turn, they are regulated by a variety of external factors, including signaling molecules, cell contacts, and the extracellular matrix. One key regulator of stem cells in various tissues, including the skin, is Wnt signaling. (Clevers, Loh, and Nusse, 2014, Science, 346(6205), 1248012 ). Wnt signaling acts on various stem cell populations in different niches, such as IFE stem cells and HF stem cells, with partially different effects (Choi et al., 2013, Cell Stem Cell, 13(6), 720-733) . In addition, it is essential for the homeostatic proliferation of stem cells but can be bypassed by other hyperproliferative inducers during inflammation. Nevertheless, Wnt signaling generally promotes the expansion of stem and progenitor cell compartments. For example, autocrine Wnt signaling stimulates the epidermis between hair follicles. (Lim et al., 2013, Science, 342(6163), 1226 - 1230 ) and follicular bulge area (Jaks et al., 2008, Nature Genetics, 40(11), 1291-1299; Lim, Tan, Yu, Lim and Nusse, 2016, Proceedings of the National Academy of Sciences of the United States of America, 113(11), E1498-505) In addition, sustained epidermal Wnt signaling can even induce ectopic hair follicles enriched with stem cells. In addition, epithelial Wnt / β-catenin signaling affects dermal zoning and promotes reprogramming of the dermis to a juvenile, neonatal state. (Collins, Kretzschmar and Watt, 2011, Development, 138(23), 5189 - 5199 ; Lichtenberger, Mastrogiannaki and Watt, 2016, Nature Communications, 7, 1 - 13). The dermal effects are increased fibroblast proliferation, ECM remodeling, maturation, and altered adipogenesis. Specifically, epidermal Wnt / β-catenin signaling drives the propagation of a “pro-regenerative” papillary fibroblast lineage (Driskell et al., 2013, Nature, 504 (7479), 277 - 281 ).

[0134] Nonetheless, Wnt signaling is context-dependent and can exacerbate pathological tissue conditions. For example, Wnt / β-catenin is a major driver of fibrosis in various tissues, including the skin. (Burgy and Königshoff, 2018, Matrix Biology, 68-69, 67-80) Constitutive activation of Wnt / β-catenin is even sufficient to induce fibrosis in various models (Burgy and K ö nigshoff, 2018, Matrix Biology, 68 - 69, 67 - 80 ). This has historically precluded simple external stimulation of Wnt signaling for cosmetic purposes. In particular, fibrosis is manifested by a disturbance in the transition of dermis-associated fibroblasts to myofibroblasts, abnormal ECM deposition, and unresolved inflammation. Therefore, spatial separation of Wnt pathway stimulation, which requires stimulation of Wnt signaling in the epidermis and the absence of stimulation in the dermis, could mitigate the problem of fibrosis induction. Such spatial control can be readily achieved in experimental model systems that allow cell-type-specific gene expression of Wnt pathway stimulatory proteins. (Lichtenberger et al., 2016, supra ). However, this type of regulation by altering the host genome is not possible for routine applications in medical or cosmetics. In contrast, pharmacological stimulators of Wnt signaling are available as small molecules. However, their efficient diffusion and bioavailability within the skin after topical application do not allow effective spatial control of activity. Therefore, current small molecule Wnt stimulators can exert their activity in the epidermis, but will also accumulate in the dermis at effective concentrations and exert their activity there. The use of natural receptor agonists or their derivatives represents an unexplored hypothetical option. However, this is complicated by the complexity of Wnt agonists, which include 19 human Wnt proteins that cross-act on at least 10 Fzd receptors and Lrp5 / 6 co-receptors. (Janda et al. , 2017, Nature, 545(7653), 234-237; Katoh, 2008, Current Drug Targets, 9 (7), 565-570; Nusse and Clevers, 2017, Cell, 169(6), 985-999) Furthermore, Wnt proteins generally require site-specific palmitoylation for activity, although this can be avoided in novel artificial fusion constructs, alternative agonists. (Janda et al., 2017, ibid. ).

[0135] The present invention discloses novel entities that stimulate Wnt / β-catenin signaling and demonstrate potential for cosmetic use. These molecules are characterized by their stability in conventional cosmetic preparations, but have a short-range activity in situ, i.e., the active variant is sufficiently available in the epidermis but not in the dermis.

[0136] These entities include:

[0137] LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL (SEQ ID NO: 1)

[0138] LNPSECPKTVLGASTSTLDASYSTAEAENHVRL (SEQ ID NO: 2)

[0139] Furthermore, these peptides can be modified at the N-terminus by fusing them to the carrier molecule Z1, thereby limiting their tissue penetration and trans-basement membrane permeation. This allows for the topical application of higher concentrations of the molecules without reaching effective concentrations beyond the basement membrane.

[0140] Z1) - LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL (SEQ ID NO: 3)

[0141] (Z1) - LNPSECPKTVLGASTSTLDASYSTAEAENHVRL (SEQ ID NO: 4)

[0142] Any size of carrier will reduce tissue penetration and transbasement membrane permeation of the peptide, thereby providing benefit. A particularly suitable carrier (Z1) is polyethylene glycol in the range of 8-60 kDa. It can be covalently coupled to the N-terminus of the peptide using NHS functionalized PEG. Regardless of the carrier type, the presentation of Wnt stimulating entities is particularly useful if the transepidermal permeation half-life is above 740 hours, thereby allowing the application of higher doses of such entities.

[0143] The transepidermal penetration half-life of such entities can be studied by measuring the concentration of such entities in the epidermis and dermis over time to generate a concentration time curve. Measurements can be made by sampling skin punch biopsies over time, separating the epidermis and dermis by surgical dissection, homogenizing and lysing the tissue sample, enriching the sample for the entity of interest by antibody-based affinity enrichment, and subjecting the enriched sample to mass spectrometry analysis for absolute quantitation.

[0144] The preferred concentration range of such carrier-conjugated Wnt agonists with a transepidermal penetration half-life of more than 740 hours in the final cosmetic product is 150 nM to 500 µM.

[0145] Matrikine Module

[0146] Matrikine is a naturally occurring molecule with biological activity in the skin that is caused by the degradation of the extracellular matrix during tissue remodeling. The role of the extracellular matrix in wound healing and scar formation has been extensively studied. (Lo, Zimmermann, Nauta, Longaker and Lorenz, 2012, Reviews, 96(3), 237-247; Marshall et al. , 2016, Advances in Wound Care, 7(2), 29-45; Xue and Jackson, 2015, Advances in Wound Care, 4(3), 119-136) Matrikine can be produced by matrix metalloproteinases (MMPs) and can also regulate various biological processes such as inflammation, immune cell chemotaxis, organ development, wound healing, ECM synthesis and angiogenesis. (Bonnans, Chou and Werb, 2014, Nature Reviews Molecular Cell Biology, 15 (12), 786-801; Bunney, PE, Zink, AN, Holm, AA, Billington, CJ, and Kotz, 2017, Physiology & Behavior, 176(205), 139-148). Together with growth factors and cytokines, matrikine has become the third pillar of active biological products for skin conditioning in cosmetics (Aldag, Teixeira and Leventhal, 2016, Cosmetic and Investigational Dermatology, 9, 411- 419) For example, commercial matrikines include the peptides GHK, GEKG, KTTKS and their acylated forms, which have been shown to stimulate general ECM synthesis or the synthesis of specific ECM proteins such as fibronectin or collagen. However, many more matrikines, including larger fragments of various ECM proteins, have been described and, to some extent, also investigated in wound healing. (Ricard-Blum and Salza, 2014, Experimental Dermatology, 23(7), 457-463) . These include fragments from aggrecan core protein, aggrecan link proteins, fibronectin, laminin, tenascin, syndecan, perlecan, elastin, tropoelastin, and various collagens, including type IV collagen alpha chain, type XIII collagen alpha chain, type XII collagen alpha chain, type XXIII collagen alpha chain, type XIX collagen alpha chain, and type XXV collagen alpha chain. Collagen proteins are some of the most abundant ECM proteins and are key regulators and markers of ECM status during physiological and pathological processes. For example, neonatal skin and non-scarring wound healing skin are known to have a high abundance ratio of type III collagen to type I collagen, whereas aged skin and scarring wound healing skin are known to have a low abundance ratio of type III collagen to type I collagen. (Marshall et al., 2016, Advances in Wound Care, 7(2), 29-45) Furthermore, reduced amounts of type III collagen have been shown to promote myofibroblast differentiation and fibrosis (Volk, Wang, Mauldin, Liechty and Adams, 2011, Cells Tissues Organs, 194(1), 25-37) Type III collagen can be degraded by matrix metalloproteinases 1, 2, 3, 8, 10, 13, 14, 16 (Sternlicht and Werb, 2001, Annual Review of Cell and Developmental Biology, 463-516 ). Matrix metalloproteinase cleavage motifs have been identified for various MMPs and most consist of roughly PXXL, PXXI, PXXV or PXXM motifs. (Eckhard et al. , 2016, Matrix Biology, 49 (2016), 37-60)。

[0147] The present invention discloses that the following peptides derived from type 3 collagen α chain 1 (consistent with the MMP cleavage sites at both ends of the type 3 collagen α chain 1 sequence) have matrikine activity and can be used for skin wound healing and cosmetic applications:

[0148] LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG (SEQ ID NO: 11)

[0149] VKGESGKPGANGLSGERGPPGPQG (SEQ ID NO: 12)

[0150] These peptides can be produced by chemical means (such as solid-state peptide synthesis) or by digestion of recombinant type 3 collagen alpha 1 protein with matrix metalloproteinases. In the latter case, these specific peptides of interest can be purified from the hydrolysate by means of liquid chromatography or by electrophoresis (such as capillary electrophoresis). Nevertheless, the crude hydrolysate can also be used in cosmetics.

[0151] Additionally, the above peptides can be acylated at the N-terminus to enhance tissue delivery:

[0152] Acyl-LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG (SEQ ID NO: 13)

[0153] Acyl-VKGESGKPGANGLSGERGPPGPQG (SEQ ID NO: 14)

[0154] Acyl may refer to any unbranched fatty acid having 5-42 carbon atoms attached to the peptide via an amide bond between the carboxyl functionality of the fatty acid and the amino functionality of the N-terminus of the peptide, such as myristoylation of the N-terminus of the peptide.

[0155] The preferred concentration range of such acylated type 3 collagen α chain 1 derived peptide in the final cosmetic is 50 pM to 500 nM.

[0156] EPOR-CD131 Hetero-Receptor Agonist Module

[0157] Agonists of EPOR / CD131 heterodimers or heterooligomers are tissue protective agents (Leist, 2004, Science, 305(5681), 239 - 242). This receptor occurs as a heterodimer or heterooligomer comprising the erythropoietin (EPO) receptor and the CD131 protein (cluster of differentiation 131, also known under the name cytokine receptor common subunit beta or the gene name CSF2RB). However, exploiting this potential has proven challenging. The natural receptor agonist erythropoietin has been abandoned as a therapeutic agent early on due to its side effects and other problems. Moreover, EPOR-CD131 agonist peptide-lipid complexes and conjugates have initially presented an ingenious alternative when used in combination with vasodilators. (Bader, 2017, PCT / EP2017 / 001289 ). These agents have been shown to be beneficial in cosmetic preparations in the short term, but have been shown to be harmful during long-term application. This can be largely attributed to a long-term overstimulation of the regenerative capacities, leading to the exhaustion of these capacities. At the molecular and cellular level, this is associated with partial stem cell exhaustion, epigenetic changes, impaired differentiation of progenitor cells into mature cells and a shift of stem cells towards a "regenerative stimulus" resistant phenotype. Therefore, the use of these agents must be strictly controlled to avoid harmful secondary effects. However, this is challenging in practice. First, the responsiveness to these agents is based on the genotypic variability of multiple proteins of the effector signaling pathway in the population. Secondly, the contribution to the undesirable long-term effects and their manifestation depends on pre-existing tissue conditions. Thirdly, personal compliance with self-application / consumption and potential compensatory reactions to declining effects present a major problem. In product trial studies, some trial individuals tried to compensate for the decline in product performance by applying more product or with a higher application frequency. However, this even exacerbated the decline. Ultimately, 58.4% of trial individuals who were initially satisfied with the product experienced a decline in the beneficial effects at various time points over a period of 9 months. In addition, 13.3% of the subjects even reported adverse effects, namely a significant deterioration of the skin condition compared to before the start of the trial.

[0158] The present invention discloses novel triggering agents that act as agonists of EPOR / CD131 heterodimer / heterooligomer receptors and do not cause the undesirable long-term effects observed in previous triggering agents of the same type. This is based on two improvements over previous agents.

[0159] The first improvement is the incorporation of a rapid inactivation mechanism that rapidly inactivates the active agent in situ (i.e. when applied to the skin). This results in a brief peak of triggering agent activity that decays immediately when the new product is applied. This time limitation of activity results in only a slight reduction in the immediate performance of the triggering agent, but also in a significant reduction in the undesirable long-term effects.

[0160] In order to achieve such a degradation mechanism but maintain the storability of the product, degradation must be initiated or sharply accelerated once the agent is applied. Typically, the time point of application coincides with the time point of leaving the storage container. This can be exploited in conjunction with the differences between the physical, chemical or biological conditions at the point of application (e.g. on the skin) compared to the conditions present in the storage container. This can be exploited according to the following strategies:

[0161] The present invention discloses novel EPOR / CD131 receptor agonists that are sensitive to oxidation, which is carried out in a suitable manner by environmental oxidants (including molecular oxygen in the air), so that oxidation-induced compound inactivation is required to be reasonably rapid after application. Due to the lack of oxidants in the storage container, oxidation-induced inactivation does not occur in the storage container.

[0162] The sequence of the peptide is as follows:

[0163] GGGGETTNMWAREWMGLPCQDQ (SEQ ID NO: 5)

[0164] The peptide can be acylated at its N-terminus to increase tissue permeability, resulting in the following structure:

[0165] Acyl-GGGGETTNMWAREWMGLPCQDQ (SEQ ID NO: 6)

[0166] Acyl may refer to any unbranched fatty acid having 5-42 carbon atoms attached to the peptide via an amide bond between the carboxyl functional group of the fatty acid and the amino functional group at the N-terminus of the peptide, such as myristoylation of the N-terminus of the peptide. Upon contact of the product with air oxygen and subsequent depletion of the antioxidant, the peptide methionine is oxidized to methionine sulfoxide, thereby inactivating the peptide.

[0167] The second improvement is the incorporation of antagonists, which also undergo equivalent degradation. In the absence of antagonists, applying more products requires applying more active agents, thereby causing stronger and longer stimulation. When there are antagonists, applying more products requires applying more active agents (i.e. agonists) and more antagonists at a constant ratio. Therefore, receptor activation and downstream signal transmission thereof can be limited, and its dependence on the amount of applied products is reduced. It is not the absolute amount of agonists and antagonists, but their receptor affinity and their potential for activation or inhibition of receptors that control the total receptor activation intensity respectively. Nevertheless, antagonists need to experience inactivation similar to agonists. If not, antagonists will become dominant after agonist inactivation. This is undesirable because it also inhibits basic endogenous signal transmission. In addition, antagonists can be accumulated by repeated product applications, thereby further increasing the ratio of active antagonists to agonists (i.e. imbalance in this case).

[0168] The sequence of a suitable antagonist compound is as follows:

[0169] GGGGETTNMWAHDWMGLPRADQ (SEQ ID NO: 17)

[0170] The peptide can be acylated at its N-terminus to increase tissue permeability, resulting in the following structure:

[0171] Acyl-GGGGETTNMWAHDWMGLPRADQ (SEQ ID NO: 10)

[0172] Acyl may refer to any unbranched fatty acid having 5-42 carbon atoms attached to the peptide via an amide bond between the carboxyl functionality of the fatty acid and the amino functionality of the N-terminus of the peptide, such as myristoylation of the N-terminus of the peptide.

[0173] The preferred concentration range of such EPOR / CD131 agonist and antagonist peptides in the final cosmetic is 30 pM to 250 nM.

[0174] Limiting fibrotic ECM remodeling through CD26 / DPP4 inhibition

[0175] The profibrotic EPF lineage is characterized by CD26 expression, and inhibition of CD26 can limit scarring after injury ( Rinkevich et al. , 2015, Science, 348(6232) ). At the cellular and molecular level, it is characterized by reduced ECM changes associated with fibrosis and decreased myofibroblast differentiation. However, because CD26 inhibition impairs the natural scarring process, wounds take longer to close and heal. Low-potency CD26 inhibitors such as dipeptidylcholine A, a slowly hydrolyzed CD26 protease substrate, have been used previously (Rinkevich et al., 2015). High-potency, orally available small molecule CD26 / Dpp4 inhibitors exist as gliptins, however gliptins are associated with severe adverse effects (Attaway, Mersfelder, Vaishnav and Baker, 2014, Journal of Dermatological Case Reports, 8 (1), 24-28; Fisman and Tenenbaum, September 29, 2015, Cardiovascular Diabetology. BioMed Central Ltd.; Nakatani et al. , 2012, Diabetes Therapy, 3(1), 1-5).

[0176] The present invention discloses novel CD26 / Dpp4 inhibitors suitable for cosmetic applications.

[0177] These include:

[0178] EIHQEEPIGGQSGSGG-KPI (SEQ ID NO: 15)

[0179] The link between G and K represents an isopeptide bond between the carboxyl function of G and the epsilon amino function of lysine. Thus, lysine has a free α-amino function.

[0180] Additionally, the peptides can be acylated to enhance tissue delivery:

[0181] EIHQEEPIGGK[acyl]SGSGG-KPI (SEQ ID NO: 16)

[0182] K[acyl] represents an amide bond between the epsilon amino functional group of lysine and the carboxyl functional group of a fatty acid. Acyl may refer to any unbranched fatty acid having 5 to 42 carbon atoms, such as myristic acid.

[0183] The preferred concentration range of such CD26 / Dpp4 inhibitor peptides in the final cosmetic product is 500 nM to 1 mM.

[0184] Combining signaling modules with trigger factor complexes

[0185] The single skin regeneration enhancing module or its specific molecule disclosed in the present invention can be used alone in cosmetics for the purpose of improving skin condition. Therefore, these modules can provide benefits independently of each other. Nevertheless, it is desirable to combine these modules in one product to release a synergistic positive effect on skin condition.

[0186] Combinations of the molecules disclosed in the present invention with conventional cosmetic ingredients

[0187] Other adjuvants and additives may be added to the cosmetic preparations to broaden or enhance the effects of the molecules according to the invention. Such agents are, for example: Pycnogenol, Coenzyme Q10, Ginseng extract, Quercetin extract, Rice bran extract, Soy extract, Algae extract, Tannins, Tea extract (especially Green tea extract), Mustard extract, Alkaloid extract from Cayenne pepper, ω-3 and ω-6 fatty acids, peptides, amino acids, vitamins (especially Vitamin E acetate), sphingolipids, ceramides, growth factors, cytokines, matrikine, vasodilators.

[0188] Cosmetic Formulations and Molecular Delivery

[0189] This innovative formulation can be combined with any cosmetic formulation, for example with any cream, lotion, serum, etc.

[0190] Efficacy trial data

[0191] The invention disclosed herein can be used in cosmetics.

[0192] In order to evaluate the efficacy of the present invention on human skin, a controlled cosmetic skin improvement study was conducted over a period of one month. In this assay, the cosmetic facial skin appearance after application of a cosmetic formulation containing the ingredients of the present invention was monitored. For this purpose, a commercially available state-of-the-art facial skin imaging and data analysis platform, Canfield Bio Visia™ ( https: / / www.canfieldsci.com / imaging-systems / visia-complexion-analysis / ). The platform provides the possibility of (i) highly standardized, (ii) highly reproducible, (iii) quantitative, iv) non-invasive and (vi) subject or experimenter-unbiased skin quality analysis. It records several facial photos from different angles and records the absorption / reflection spectra. Using these data, the platform quantifies several parameters of skin quality, including "spots", "wrinkles", "pores", "smoothness", "UV spots" and "brown spots". The built-in software standardizes each parameter by comparing it to a large database of skin feature benchmarks and returns a percentage value to allow inter-subject comparison. Healthy subjects receive a standard cosmetic base formulation with or without a trigger factor complex in a blinded manner (i.e., the subject does not know the identity of the cosmetic cream received). The cosmetic base formulation contains water, caprylic triglyceride, pentylene glycol, propylene glycol, hydrogenated phosphatidylcholine, ceramides, tocopheryl acetate, sodium ascorbate, vasodilators, matrikine, amino acids, ethanol and glycerol. The subject is instructed to apply the cream twice a day and the amount of application is indicated. The skin quality of the subjects was assessed before the start of application and one month later (30 ± 3 days). As a control, the quality of the outer surface of the hands was also monitored in order to account for changes in skin quality associated with seasonal and lifestyle changes. There was no statistically significant change in the skin quality of the outer surface of the hands in any of the subjects included in the analysis, thus indicating that the determination timeline in overall skin quality was not associated with any lifestyle or seasonal changes. This study yielded the results described in the "Data 1: Short-term study" section. In addition, the long-term effects of cosmetics containing trigger factor complexes on facial skin were studied in two nine-month long-term studies, in which product doses and application frequency were freely selected by the test subjects to reflect commercial realities. The cosmetic base formulation was the same as that used in the one-month study. Study participants regularly reported their subjective impressions of their skin status, product effects and side effects at any time point during the study, and reported when they noticed changes. In particular, participants reported their impressions of how the performance of the cosmetics remained the same or changed during the study. The difference between the two studies is the exact trigger factor complex used, which is detailed in the "Data 2: Long-term study 1" and "Data 3: Long-term study 2" sections below together with the study results. Example

[0193] The cosmetic performance information of 4 trigger factor complexes (TFC8-A, TFC8-B, TFC8-C, TFC8-D) obtained in a one-month controlled study is disclosed. The molecules contained in these trigger factor complexes are listed in Tables 1-4. TFC8-A and TFC8-C differ only in the molecules of the stem cell homeostasis module. Similarly, TFC8-B and TFC8-D differ only in the molecules of the stem cell homeostasis module.

[0194] Embodiment 1: The following trigger factor complex 1 (TFC8-A) is composed of:

[0195]

[0196] Example 2 : The following trigger factor complex 2 (TFC8-B) is composed of:

[0197]

[0198] Example 3 : The following trigger factor complex 3 (TFC 8C) consists of:

[0199]

[0200] Example 4 : The following trigger factor complex 4 (TFC 8D) is composed of:

[0201]

[0202] Study Results ( like Figure 1 and 2 shown):

[0203] Short-term studies ( Figure 1 )

[0204] The trigger factor complexes TFC8-A, TFC8-B, TFC8-C and TFC8-D as detailed above were applied to a controlled cosmetic application study over a period of one month. The conditions and implementation are described above in the "Efficacy Test Data" section.

[0205] The results of a one-month controlled study are as follows Figure 1 As shown, the figure depicts the percentage change of the normalized "Visia" score (y-axis) relative to seven categories of skin appearance (x-axis), which are here: spots (1), wrinkles (2), UV spots (3), brown spots (4), pores (5), red blood vessel formation (6) and smoothness (7). The skin appearance of all four triggering complexes described in detail is shown (the "Visia" score test is described in the "Efficacy Test Data" section above). The changes are related to the normalized difference of the values ​​(normalized value after 1 month of application - normalized value before application). The bars depict the average normalized changes and the error bars depict the standard deviation. All changes are statistically significantly (p-value < 5%) different from 0. In addition, all changes are statistically significantly (p-value < 5%) different from the changes observed in the subjects who received the vehicle control cosmetic base formulation without any triggering factor complex. All cosmetic formulations containing the trigger factor complex resulted in an improvement in skin appearance as measured by skin parameters reported by the Canfield Bio Visia device over a test period of 30 ± 3 days.

[0206] Long-term research

[0207] Study 1 :The trigger factor complexes TFC8-A, TFC8-B, TFC8-C and TFC8-D as described in detail in the "Examples" section above were also applied to a 9-month cosmetic application study. The conditions and implementation are described in the "Efficacy Test Data" section above. The trigger factor complex also performed well in the first 9-month long-term application study, in which the product dosage and application frequency were freely selected by the test subjects, indicating a wide range of consumer product applicability. All four trigger factor complexes were associated with a low risk of overstimulation of stem cell regeneration and subsequent exhaustion. Overall, only 7.2% of the test subjects reported a decrease in product performance, and only 1.6% of the test subjects reported a significant deterioration in the subjectively perceived skin condition during the test period. No significant adverse effects were reported.

[0208] Study 2 Figure 2 ): To further investigate the role of the stem cell homeostasis module molecules of the trigger factor complex in the effects of long-term product application on skin condition, another 9-month long-term study was conducted. The conditions and implementation are described in the "Efficacy Test Data" section above. In order to ensure comparability and to specifically investigate the four peptides of the stem cell homeostasis module (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4), these four peptides were combined with the same set of molecules of the other modules as detailed in the trigger factor complex TFC8-D in the "Examples" section above for testing. As previously mentioned, the carrier in the peptide derivatives SEQ ID NO: 3 and SEQ ID NO: 4 is polyethylene glycol with a molecular weight of 35 kDa. This second long-term study revealed that the stem cell homeostasis module molecules had different correlations with the decline in product performance during the study. The frequency of reported product performance declines associated with each of the four peptides is as follows. Figure 2 Error bars represent 95% confidence intervals for observed frequencies.

[0209] Overall, the amino acid sequence of SEQ ID NO: 2 (also contained in SEQ ID NO: 4) was more strongly associated with a decrease in product performance during the study period than the sequence of SEQ ID NO: 1 (also contained in SEQ ID NO: 3). These differences were statistically significant (p-value < 5%). Secondly, the polyethylene glycol carrier moderately reduced the frequency of product performance decreases in the case of both amino acid sequences. Thus, the frequency of SEQ ID NO: 3 was lower than that of SEQ ID NO: 1, and the frequency of SEQ ID NO: 4 was lower than that of SEQ ID NO: 2.

Claims

1. A cosmetic preparation for topical application to the skin that enhances or improves skin regeneration or appearance, wherein the preparation comprises: (i) a peptide fusion molecule that is a variant of human transforming growth factor β3 (TGF-β3) and has the sequence or formula described below: SEQ ID NO:9:ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCS-GPCPYLRSADTKHSTVLGLYNTHNPEAASASPCCVPQDLEPLTILYYV-GRTPKVEQLENMVVKSCKCSLPXTGGG-Z3 Where X is E, and Z3 is an oligomer composed of 18-30 moieties of trehalose or trehalose derivatives, and (ii) a peptide provided to stimulate the Wnt / β-catenin signaling pathway in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:2: LNPSECPKTVLGASTSTLDASYSTAEAENHVRL, or SEQ ID NO:4: Z1-LNPSECPKTVLGASTSTLDASYSTAEAENHVRL, or SEQ ID NO:1: LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL, or SEQ ID NO:3:Z1-LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL, wherein Z1 is polyethylene glycol (PEG) having a molecular weight in the range of 20-40 kDa coupled to the N-terminus; and (iii) a first peptide fusion molecule, which is provided to act as an agonist of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor in the cosmetic preparation and has the sequence or formula described below: SEQ ID NO:6: Z2-GGGGETNMWAREWMGLPCQDQ, and A second peptide fusion molecule, which is provided to act as an antagonist of the receptor in the cosmetic preparation, has the sequence or formula described below: SEQ ID NO:10:Z2–GGGGETTNMWAHDWMGLPRADQ, wherein Z2 is a myristoyl group attached to the N-terminus of the peptide; and (iv) a peptide which is provided to cause CD26 / Dpp4 inhibition in the cosmetic preparation and has a sequence or formula as described below: SEQ ID NO: 15: EIHQEEPIGGQSGSGG-KPI, or SEQ ID NO:16:EIHQEEPIGGK[Z2]SGSGG-KPI wherein GK represents an isopeptide bond between the carboxyl functional group of G and the epsilon amino functional group of K, and Z2 is a myristoyl group attached to the epsilon amino functional group of K, (v) two peptides, which are provided to induce type 3 collagen-derived matrikine activity in the cosmetic preparation and have the sequence or formula described below: SEQ ID NO:11: LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG, and SEQ ID NO:12: VKGESGKPGANGLSGERGPPGPQG, or SEQ ID NO:13: Z2-LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG, and SEQ ID NO:14:Z2-VKGESGKPGANGLSGERGPPGPQG wherein Z2 is a myristoyl group attached to the N-terminus of the peptide.

2. The cosmetic preparation according to claim 1, wherein Z3 of SEQ ID NO: 9 is: [4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose] 18 ,or [Q-6-deoxy-trehalose] 18 .

3. The cosmetic preparation according to claim 1, wherein Z1 of SEQ ID NO: 3 and 4 is 35 kD PEG.

4. The cosmetic preparation according to claim 1, wherein the preparation is named "TFC8-A" and comprises: (i) A peptide fusion molecule which is a variant of human transforming growth factor β3 (TGF-β3) and has the sequence or formula described below: SEQ ID NO:18:ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCS-GPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYV-GRTPKVEQLENMVVKSCKCSLPETGGG-[4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose] 18 ,and (ii) a peptide provided to stimulate the Wnt / β-catenin signaling pathway in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:2:LNPSECPKTVLGASTSTLDASYSTAEAENHVRL, and (iii) a first peptide fusion molecule, which is provided to act as an agonist of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor in the cosmetic preparation and has the sequence or formula described below: SEQ ID NO:6:Z2-GGGGETNMWAREWMGLPCQDQ, and A second peptide fusion molecule, which is provided to act as an antagonist of the receptor in the cosmetic preparation, has the sequence or formula described below: SEQ ID NO:10:Z2–GGGGETTNMWAHDWMGLPRADQ, wherein Z2 is a myristoyl group attached to the N-terminus of the peptide, and (iv) a peptide provided to cause CD26 / Dpp4 inhibition in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:15EIHQEEPIGGQSGSGG-KPI, where G–K represents an isopeptide bond between the carboxyl functional group of G and the epsilon amino functional group of K, and (v) two peptides provided to induce type 3 collagen-derived matrikine activity in the cosmetic preparation and having the sequence or formula described below: SEQ ID NO:11: LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG, and SEQ ID NO:12: VKGESGKPGANGLSGERGPPGPQG.

5. The cosmetic preparation according to claim 1, wherein the preparation is named "TFC8-B" and comprises: (i) A peptide fusion molecule which is a variant of human transforming growth factor β3 (TGF-β3) and has the sequence or formula described below: SEQ ID NO:19: ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCS-GPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYV-GRTPKVEQLENMVVKSCKCSLPETGGG-[Q-6-deoxy-trehalose] 18 , and (ii) a peptide provided to stimulate the Wnt / β-catenin signaling pathway in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:4:Z1-LNPSECPKTVLGASTSTLDASYSTAEAENHVRL, Wherein Z1 is a 35 kDa polyethylene glycol coupled to the N-terminus, and (iii) a first peptide fusion molecule provided to act as an agonist of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor in the cosmetic preparation, the peptide fusion molecule having the sequence or formula described below: SEQ ID NO:6:Z2-GGGGETNMWAREWMGLPCQDQ, and A second peptide fusion molecule, which is provided to act as an antagonist of the receptor in the cosmetic preparation, has the sequence or formula described below: SEQ ID NO:10:Z2–GGGGETTNMWAHDWMGLPRADQ, wherein Z2 is a myristoyl group attached to the N-terminus of the peptide, and (iv) a peptide provided to cause CD26 / Dpp4 inhibition in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:16:EIHQEEPIGGK[Z2]SGSGG-KPI wherein G–K represents an isopeptide bond between the carboxyl functional group of G and the epsilon amino functional group of K, and Z2 is a myristoyl group attached to the epsilon amino functional group of K, and (v) two peptides provided to induce type 3 collagen-derived matrikine activity in the cosmetic preparation and having the sequence or formula described below: SEQ ID NO:13: Z2-LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG, and SEQ ID NO:14:Z2-VKGESGKPGANGLSGERGPPGPQG wherein Z2 is a myristoyl group attached to the N-terminus of the peptide.

6. The cosmetic preparation according to claim 1, wherein the preparation is named "TFC8-C" and comprises: (i) A peptide fusion molecule which is a variant of human transforming growth factor β3 (TGF-β3) and has the sequence or formula described below: SEQ ID NO:18: ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCS-GPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYV-GRTPKVEQLENMVVKSCKCSLPXTGGG-[4,6-O-(4-vinylbenzylidene)-α,α-D-trehalose] 18 , where X is E, and (ii) a peptide provided to stimulate the Wnt / β-catenin signaling pathway in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:1:LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL, and (iii) a first peptide fusion molecule provided to act as an agonist of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor in the cosmetic preparation, the peptide fusion molecule having the sequence or formula described below: SEQ ID NO:6:Z2-GGGGETNMWAREWMGLPCQDQ, and A second peptide fusion molecule, which is provided to act as an antagonist of the receptor in the cosmetic preparation, has the sequence or formula described below: SEQ ID NO:10:Z2–GGGGETTNMWAHDWMGLPRADQ, wherein Z2 is a myristoyl group attached to the N-terminus of the peptide, and (iv) a peptide provided to cause CD26 / Dpp4 inhibition in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:15EIHQEEPIGGQSGSGG-KPI, where G–K represents an isopeptide bond between the carboxyl functional group of G and the epsilon amino functional group of K, and (v) two peptides provided to induce type 3 collagen-derived matrikine activity in the cosmetic preparation and having the sequence or formula described below: SEQ ID NO:11: LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG, and SEQ ID NO:12: VKGESGKPGANGLSGERGPPGPQG.

7. The cosmetic preparation according to claim 1, wherein the preparation is named "TFC8-D" and comprises: (i) A peptide fusion molecule which is a variant of human transforming growth factor β3 (TGF-β3) and has the sequence or formula described below: SEQ ID NO:19: ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCS-GPCPYLRSADTKHSTVLGLYNTHNPEASASPCCVPQDLEPLTILYYV-GRTPKVEQLENMVVKSCKCSLPXTGGG-[Q-6-deoxy-trehalose] 18 , where X is E, and (ii) a peptide provided to stimulate the Wnt / β-catenin signaling pathway in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO:3:Z1-LNPSECPKTVLGAEYGKTLDASYSTAEAENHVRL, wherein Z1 is a 35 kDa polyethylene glycol coupled to the N-terminus, and (iii) a first peptide fusion molecule provided to act as an agonist of the tissue protective heterodimer or heterooligomer EPOR / CD131 (erythropoietin receptor / cluster of differentiation 131) receptor in the cosmetic preparation, the peptide fusion molecule having the sequence or formula described below: SEQ ID NO:6:Z2-GGGGETNMWAREWMGLPCQDQ, and The second peptide fusion molecule, which is provided to act as an antagonist of the receptor in the cosmetic preparation, has the sequence or formula described below SEQ ID NO:10:Z2–GGGGETTNMWAHDWMGLPRADQ, wherein Z2 is a myristoyl group attached to the N-terminus of the peptide, and (iv) a peptide provided to cause CD26 / Dpp4 inhibition in the cosmetic preparation and having a sequence or formula as described below: SEQ ID NO: 16: EIHQEEPIGGK[Z2]SGSGG-KPI, and (v) two peptides provided to induce type 3 collagen-derived matrikine activity in the cosmetic preparation and having the sequence or formula described below: SEQ ID NO:13: Z2-LQGLPGTGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPG, and SEQ ID NO:14:Z2-VKGESGKPGANGLSGERGPPGPQG wherein Z2 is a myristoyl group attached to the N-terminus of the peptide.

Citation Information

Patent Citations

  • Display apparatus

    EP3280130A1

  • Cosmetic formulations for topical applications containing erythropoietin-derived molecules

    US10456346B2

  • Cosmetic formulations for topical applications containing erythropoietin-derived molecules

    WO2018086732A1

  • Peptides for skin rejuvenation and methods of using the same

    CN105189531A

  • Tetrapeptides derived from human C-X-C chemokines useful for treatment of various skin conditions

    CN105324122A